Response of GEM models of neuroblastoma to cabozantinib assessed by multiparametric magnetic resonance imaging by Gilberto S. Almeida, Philippa King, Albert Hallsworth, Hannah Webber, Sergey Popov, Susana Miranda, Orli Yogev, Andrew D.J. Pearson, Louis Chesler, Yann Jamin, Simon P. Robinson

Subjects: Get full text

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, a... by Andrea S. Fung, Vincent C. Tam, Daniel E. Meyers, Hao‐Wen Sim, Jennifer J. Knox, Valeriya Zaborska, Janine Davies, Yoo‐Joung Ko, Eugene Batuyong, Haider Samawi, Winson Y. Cheung, Richard Lee‐Ying

Subjects: “…cabozantinib…”
Get full text

Systemic treatments for hepatocellular carcinoma: challenges and future perspectives by Francesco Tovoli, Giulia Negrini, Francesca Benevento, Chiara Faggiano, Elisabetta Goio, Alessandro Granito

Subjects: “…cabozantinib…”
Get full text

Patient advocacy and the future of systemic therapies in liver cancer: an interview with Ghassan Abou-Alfa by Ghassan Abou-Alfa

Subjects: Get full text

Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular CarcinomaSummary by Ting-Chi Rebecca Wan, Lai Wei, Lai-Hung Cheng, Wai-Ching Chin, Jialing Shen, For-Fan Chan, Zhijian Kuang, Cun Wang, Carmen Chak-Lui Wong, Chun-Ming Wong

Subjects: “…Cabozantinib…”
Get full text

Side skin reactions of multikinase inhibitors in treatment of thyroid cancer by F. S. Sevryukov, E. V. Borodavina, Р. А. Isaev, V. V. Polkin, А. А. Ilyin, S. V. Vasilkov, Yu. А. Panaseykin, D. N. Derbugov, S. А. Ivanov, S. О. Podvyaznikov, А. D. Kaprin

Subjects: Get full text

Overexpression of c-Myc triggers p62 aggregation-mediated mitochondrial mitophagy in cabozantinib resistance of hepatocellular carcinoma by Kaibo Yang, Xing Zhang, Kun Yang, Sinan Liu, Jingyao Zhang, Yunong Fu, Tong Liu, Kunjin Wu, Jing Li, Chang Liu, Qichao Huang, Kai Qu

Subjects: Get full text

Efficacy of cabozantinib and sunitinib for the treatment of intermediate/poor risk renal cell carcinoma based upon UK real-world data by D. Lee, G.J. Melendez-Torres, A. Challapalli, R. Frazer, J. McGrane, A. Bahl

Subjects: Get full text

A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers by Guilherme Harada, MD, Fernando C. Santini, MD, Clare J. Wilhelm, PhD, Rebecca W. Repetti, NP, Jason C. Chang, MD, Soo-Ryum Yang, MD, Yun-Te Lin, MSc, Khadeja A. Moses, BA, Christina Falcon, MPH, PMP, Michelle Goldstein, MSW, Alex Makhnin, MA, Michelle S. Ginsberg, MD, Andrew J. Plodkowski, MD, Mark G. Kris, MD, Alexander Drilon, MD

Subjects: “…Cabozantinib…”
Get full text

Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series by Marilda Mormando, Rosa Lauretta, Giulia Puliani, Marta Bianchini, Maria Elena Spoltore, Marialuisa Appetecchia

Subjects: Get full text

Real-world efficacy of cabozantinib alone or in combination with ICIs in heavily pretreated hepatocellular carcinoma: potential role of AXL and MET expression by Kuan-Chang Lai, Te-Lin Hsu, Shih-Yao Lin, Nai-Jung Chiang, Ming‑Huang Chen, Yee Chao, Muh-Hwa Yang, San-Chi Chen

Subjects: Get full text

Real world data of cabozantinib in patients with hepatocellular carcinoma: Focusing on dose setting and modification by Hironao Okubo, Hitoshi Ando, Shunsuke Nakamura, Yusuke Takasaki, Koichi Ito, Yuka Fukuo, Kenichi Ikejima, Hiroyuki Isayama

Subjects: Get full text

Renal cell carcinoma: An update for the practicing urologist by Sumanta K. Pal, Paulo Bergerot, Robert A. Figlin

Subjects: Get full text

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) by Matteo Santoni, Giandomenico Roviello, Enrique Grande, Ugo De Giorgi, Ondrej Fiala, Emmanuel Seront, Javier Molina-Cerrillo, Renate Pichler, Zin W. Myint, Jakub Kucharz, Ravindran Kanesvaran, Thomas Büttner, Martin Pichler, Umberto Basso, Jindrich Kopecky, Maria T. Bourlon, Linda Cerbone, Tomas Buchler, Alvaro Pinto, Alfonso Gómez de Liaño, Caterina Gianni, Anca Zgura, Pasquale Rescigno, Jawaher Ansari, Orazio Caffo, Zsófia Küronya, Maria Giuseppa Vitale, Dipen Bhuva, Martina Catalano, Nuno Vau, Ray Manneh Kopp, Sebastiano Buti, Aristotelis Bamias, Camillo Porta, Kaisa Sunela, Francesco Massari

Subjects: Get full text

Designing novel cabozantinib analogues as p-glycoprotein inhibitors to target cancer cell resistance using molecular docking study, ADMET screening, bioisosteric approach, and mole... by Gajendra Singh Thakur, Ajay Kumar Gupta, Dipti Pal, Yogesh Vaishnav, Neeraj Kumar, Sivakumar Annadurai, Sanmati Kumar Jain

Subjects: Get full text

Cabozantinib-Associated Exudative Retinal Detachment and Choroiditis: A Case Report by Kirk A.J. Stephenson, Bryon R. McKay, Katherine E. Paton

Subjects: “…cabozantinib…”
Get full text

Postmortem genetic diagnosis of hereditary leiomyomatosis and renal cell carcinoma syndrome: Identification through normal kidney tissues after surgical removal by Shodai Suzuki, Yoshiyuki Yamamoto, Taigo Kato, Koji Hatano, Takahiro Matsui, Kae Hashimoto, Takako Miyamura, Yoji Nagashima, Norio Nonomura, Atsunari Kawashima

Subjects: “…cabozantinib…”
Get full text

Combined Use of Cabozantinib and Nivolumab in Clinical Practice by V. E. Askarov, A. V. Sultanbaev, K. V. Menshikov, Sh. I. Musin, N. I. Sultanbaeva, E. V. Popova, I. A. Menshikova

Subjects: Get full text

The significance of therapeutic drug monitoring in detecting low medication adherence in patients with cancer: A case study of cabozantinib by Shinichi Maruyama, Kenji Momo, Tadatsugu Anno, Masaru Ishida, Hiroshi Kanno, Masaru Kato

Subjects: “…cabozantinib…”
Get full text

Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study by Maria T. Bourlon, Maria T. Bourlon, Luca Galli, Enrique Grande, Se Hoon Park, Bohuslav Melichar, Timothy J. Schieber, Maria José Juan-Fita, Yüksel Ürün, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Ugo De Giorgi, Jakub Kucharz, Esther Pérez Calabuig, Vincenza Conteduca, Tarek Taha, Tarek Taha, Pasquale Rescigno, Hussam Abu-Sini, Gian Paolo Spinelli, Ray Manneh Kopp, Alessia Salfi, Dipen Bhuva, Paola Valdez-Sandoval, Sofia Mendez-Bribiesca, Ondrej Fiala, Ondrej Fiala, Sebastiano Buti, Sebastiano Buti, Fernando Sabino Marques Monteiro, Fernando Sabino Marques Monteiro, Aristotelis Bamias, Marwan Ghosn, Francesco Massari, Francesco Massari, Jawaher Ansari, Matteo Santoni

Subjects: “…nivolumab plus cabozantinib…”
Get full text